Therapeutic index Study Guide

📖 Core Concepts Therapeutic Index (TI) / Therapeutic Ratio – quantitative safety measure: $$\text{TI}{\text{safety}} = \frac{TD{50}}{ED{50}}$$ where TD₅₀ = dose causing toxic effects in 50 % of subjects, ED₅₀ = dose producing the desired effect in 50 % of subjects. Therapeutic Window (Safety Window) – the dose range between minimal effective concentration and onset of unacceptable toxicity. Protective Index (PI) – uses TD₅₀ instead of LD₅₀: $$\text{PI} = \frac{TD{50}}{ED{50}} = \frac{1}{\text{TI}{\text{safety}}}$$ Margin of Safety (Certain Safety Factor) – uses extreme ends of the dose‑response curve: $$\text{MoS} = \frac{LD{1}}{ED{99}}$$ Maximum Tolerated Dose (MTD) – highest dose that can be given without unacceptable toxicity; guides dose‑finding in trials. Optimal Biological Dose (OBD) – dose that gives maximal therapeutic effect while staying inside the acceptable toxicity range. Radiotherapy Therapeutic Ratio – ratio of tumor‑killing dose to normal‑tissue morbidity dose; depends on the steepness of the respective dose‑response curves. --- 📌 Must Remember Higher TI (safety‑based) → larger gap between effective and toxic doses → safer drug. Narrow therapeutic window → small difference between ED₅₀ and TD₅₀ → requires therapeutic drug monitoring (TDM). Protective Index is the reciprocal of the safety‑based TI. LD₅₀ (median lethal dose) is historical; modern clinical TI uses TD₅₀ (toxicity) rather than lethality. Steady‑state exposure must be used for drugs whose toxicity accumulates over multiple doses. In radiotherapy, tumor curve steeper than normal‑tissue curve → better therapeutic ratio. Cell‑cycle radiosensitivity: S‑phase (most resistant) → M‑phase (most sensitive). Margin of Safety uses LD₁ / ED₉₉ → gives a stricter safety estimate than LD₅₀ / ED₅₀. --- 🔄 Key Processes Calculate Clinical TI (safety‑based) Determine ED₅₀ (dose for 50 % therapeutic response). Determine TD₅₀ (dose for 50 % toxic response). Compute TI = TD₅₀ / ED₅₀. Convert to Protective Index PI = 1 / TI (or directly compute TD₅₀ / ED₅₀ if not already done). Assess Margin of Safety Find LD₁ (dose lethal to 1 % of population). Find ED₉₉ (dose effective in 99 % of population). Compute MoS = LD₁ / ED₉₉. Radiotherapy Therapeutic Ratio Optimization Plot tumor‑control and normal‑tissue toxicity dose‑response curves. Choose modalities (IMRT, proton, heavy‑ion) that lower normal‑tissue dose for the same tumor dose. Add radiosensitizers (e.g., PARP inhibitors) to increase tumor curve steepness or radioprotectors (e.g., EGFR inhibitors) to flatten normal‑tissue curve. Determine MTD in a Clinical Trial Start with low dose, incrementally increase in cohorts. Monitor for dose‑limiting toxicities (DLTs). The highest dose with ≤ acceptable DLTs = MTD. --- 🔍 Key Comparisons TI (safety‑based) vs. PI TI = TD₅₀ / ED₅₀ (higher = safer). PI = TD₅₀ / ED₅₀ = 1 / TI (higher PI = less safe if interpreted like TI). LD₅₀ vs. TD₅₀ LD₅₀ = dose lethal to 50 % (historical toxicology). TD₅₀ = dose causing any toxic effect in 50 % (clinical relevance). Therapeutic Window vs. Therapeutic Ratio (radiotherapy) Window = dose range for a single drug. Ratio = comparison of tumor‑killing vs. normal‑tissue morbidity doses. Narrow vs. Wide Therapeutic Window Narrow → high risk of toxicity, need TDM. Wide → larger safety margin, less monitoring. --- ⚠️ Common Misunderstandings “Higher TI always better.” True only when both ED₅₀ and TD₅₀ are measured under the same conditions; a high TI can mask variability in exposure. Confusing PI with TI. PI is the reciprocal; a PI > 1 does not mean a safer drug. Assuming LD₅₀ = TD₅₀. LD₅₀ measures lethality, TD₅₀ measures any toxicity—different clinical implications. Thinking the therapeutic ratio only concerns dose. It also depends on dose‑response curve shape and fractionation in radiotherapy. Neglecting drug‑drug interactions. Therapeutic index does not account for synergistic toxicities. --- 🧠 Mental Models / Intuition “Gap model” – Visualize ED₅₀ and TD₅₀ as two points on a line; the larger the gap, the safer the drug. “Reciprocal mirror” – TI and PI are reflections across the line = 1; flipping one gives the other. Radiotherapy “steep‑vs‑flat” – Imagine two hills: a steep tumor hill (small dose change → big effect) and a flat normal‑tissue hill (dose must rise a lot before toxicity). The steeper the tumor hill relative to normal tissue, the better the therapeutic ratio. Cell‑cycle “radio‑sensitivity ladder” – S (bottom, resistant) → G1 → G2/M → M (top, sensitive). --- 🚩 Exceptions & Edge Cases Protective Index superiority – When toxicity occurs far below lethal levels, PI gives a clearer safety picture than the classic TI. Margin of Safety vs. TI – For substances with both beneficial and adverse effects across the dose range, MoS (LD₁ / ED₉₉) is more stringent than TI. Steady‑state exposure – For drugs with cumulative toxicity, single‑dose TD₅₀ underestimates risk; use steady‑state concentration. Patient‑centric MTD limits – Real‑world tolerability may be lower than the trial‑determined MTD due to non‑toxic side effects (e.g., emotional blunting). --- 📍 When to Use Which Safety‑based TI – Use for approved drugs where clinical dose‑response data (ED₅₀, TD₅₀) are available. Protective Index – Prefer in early‑stage drug development or when lethal data are unavailable but sub‑lethal toxicity is critical. Margin of Safety – Apply when evaluating chemicals with both therapeutic and harmful effects across the whole population spectrum. Therapeutic Ratio (radiotherapy) – Use when planning radiation treatment plans, especially with advanced modalities (IMRT, proton). Maximum Tolerated Dose – Required in phase I clinical trials to define dose‑limiting toxicity thresholds. --- 👀 Patterns to Recognize Sigmoidal dose‑response for both efficacy and toxicity; look for the steeper curve (tumor) vs. flatter curve (normal tissue). Radio‑sensitivity pattern across cell‑cycle phases: M > G2/M > G1 > S. Narrow therapeutic window → frequent mention of TDM, frequent dosing adjustments, or dose‑related adverse events in stem. Steady‑state vs. single‑dose phrasing: if toxicity “accumulates,” expect steady‑state calculations. --- 🗂️ Exam Traps Trap 1: Choosing LD₅₀ / ED₅₀ as the TI formula – the correct clinical TI uses TD₅₀, not LD₅₀. Trap 2: Assuming a higher PI means a safer drug – remember PI = 1 / TI; a higher PI actually indicates a lower safety‑based TI. Trap 3: Confusing therapeutic window with therapeutic ratio – the window is a dose range for a drug; the ratio compares tumor vs. normal‑tissue doses in radiotherapy. Trap 4: Ignoring steady‑state exposure for drugs with cumulative toxicity – the exam may present a single‑dose TD₅₀ and ask for the appropriate TI; answer: use steady‑state TD₅₀. Trap 5: Selecting the maximum tolerated dose as the optimal biological dose – MTD is the highest tolerable dose; OBD may be lower to stay within the therapeutic window. Trap 6: Overlooking drug‑drug interactions – a question may give a high TI but also list a known synergistic toxic interaction; the correct answer will note that TI does not capture this risk. ---